No Data
No Data
Craig-Hallum Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4
Ascendiant Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Raises Target Price to $7.5
Ascendiant Reaffirms Their Buy Rating on Atossa Therapeutics (ATOS)
Express News | Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.5
Craig-Hallum Initiates Atossa Therapeutics(ATOS.US) With Buy Rating, Announces Target Price $4
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday